retatrutide resukts 28.7% Weight Loss in New Study – Dr Brad Stanfield The TRIUMPH-1 Phase 3 results

Given that the Phase I clinical trial in IPF demonstrated a reduction of senescent cells and SASP within eleven days after a single treatment of D+Q, and improvements in physiological outcomes after 10 weeks (105), we reasoned that a three-month period would provide important feasibility, compliance and efficacy data, as well as potentially reveal other cognitive and biomarker effects useful for designing a larger study

10.1111/dom.12742 198 TianJ.BaiB.GaoZ.YangY.WuH.WangX.et al (2021)

Behind the scenes, it activates pathways like AMPK and GLP-1 that keep blood sugar more stable throughout the day

That exception created a large and fast-growing compounded GLP-1 market - with programs priced at $150-$300 per month versus $1,000+ for brand-name alternatives